See Also: U.S. Guidelines for HIV Testing, Prevention, and Treatment; Starting HIV Treatment; Changing Treatment Regimens; Salvage Treatment for HIV; Innovative Approaches to HIV Treatment
Selected Recent Articles
- Integrase inhibitors associated with improved viral suppression in HIV. (September 2016, Healio)
- ViiV Begins Phase III Trial of Two-Drug HIV Regimen. (August 2016, Poz)
- Tenofovir Levels in Blood 4-Fold Higher With TAF Than TDF. (July 2016, TheBodyPro)
- Dolutegravir Superior in Women-Only Study. (July 2016, TheBodyPro)
- Dolutegravir plus lamivudine dual therapy works well as initial HIV treatment. (July 2016, AIDSmap); related coverage from MedPage Today
- Complera Non-inferior to Atripla. (July 2016, MedPage Today)
- Darunavir plus cobicistat demonstrates safety, efficacy in younger, older patients. (July 2016, Healio)
- Women-Only Trial Boosts HIV Combo. (July 2016, MedPage Today)
- For Women with HIV, Triumeq Is Superior to Norvir–Boosted Reyataz Plus Truvada. (July 2016, Poz)
- TAF, combination regimens improve outcomes in HIV, but challenges remain. (July 2016, Healio)
- TAF-based regimen demonstrates safety, efficacy in patients with diabetes, renal impairment. (June 2016, Healio)
- Darunavir Plus Cobicistat Works Well in Older HIV Groups. (June 2016, Medpage Today)
- Taking Atripla Three Days a Week Maintains Undetectable HIV Viral Load, Pilot Study Finds. (June 2016, TheBodyPro)
- Switching to TAF Noninferior to Continuing TDF in Double-Blind Trial. (June 2016, TheBodyPro)
- Early results show doravirine regimen as effective as efavirenz regimen. (March 2016, Project Inform)
- ‘Explosion of options’ in single-tablet regimens for HIV benefits patients, providers. (March 2016, Healio)
- Switching to Emtricitabine/TenofovirAlafenamide (F/TAF) Maintains Viral Suppression with Better Bone and KidneySafety. (February 2016, TheBodyPro); related coverage from AIDSmap and Project Inform
- Tivicay/lamivudine regimen more cost-effective than standard ART. (January 2016, Healio)
- Two-drug ART with dolutegravir-lamivudine would be cost-effective and achieve substantial cash savings. (December 2015, AIDSmap)
- First TAF-based HIV regimen simplifies treatment, reduces toxicity. Video dated December 2015, Healio)
- Another Two-Drug HIV Regimen Shows Promise. (December 2015, Poz)
- Two-drug maintenance therapy keeps viral load suppressed and may even have advantages over traditional ART. (November 2015, AIDSmap)
- Switching to Abacavir/Dolutegravir/Lamivudine (Triumeq) Maintains Undetectable Viral Load. (October 2015, TheBodyPro)
- ICAAC 2015: Stribild Superior for Women; Better Safety & Efficacy of TAF. (October 2015, Beta Blog)
- Rilpivirine + darunavir HIV maintenance regimen matches standard three-drug antiretroviral therapy. (September 2015, AIDSmap)
- WAVES shows elvitegravir regimen beats boosted atazanavir for women with HIV. (August 2015, AIDSmap)
- New HIV Med Doravirine Has Half of Sustiva’s Side Effect Rate. (July 2015, Poz)
- HIV Antiretroviral Study Highlights From IAS 2015. (July 2015, TheBodyPro)
- Early ART proves more beneficial than deferred treatment. (May 2015, Healio)
- Solid Evidence Backing Early HIV Treatment Finally Arrives. (May 2015, Poz)
- START trial finds that early treatment improves outcomes for people with HIV. (May 2015, AIDSmap)
- Lower daily tenofovir dose of 150mg safe and effective in people with moderate renal impairment. (May 2015, AIDSmap)
- Isentress causes less bone density loss than PIs. (May 2015, Healio)
- Individual HIV Meds Are Just as Effective as Combo Pills. (May 2015, Poz)
- Treatment outcomes no better with single tablet regimens than individual tablets. (April 2015, AIDSmap)
- HIV Treatment Guidelines Nix Atripla as First-Line Therapy. (April 2015, Poz)
- Ritonavir concentrations not correlated with lipid levels in people with HIV taking boosted atazanavir or boosted darunavir. (April 2015, AIDSmap)
- Dolutegravir Shows Promise as Part of First-Line HIV Therapy. (March 2015, Beta Blog)
- Dutch ATHENA study announces surprising results when using 3TC (lamivudine) over FTC (emtricitabine) (March 2015, Project Inform)
- Novel HIV Prodrug Safer Than Its Predecessor. (February 2015, MedPage Today)
- 3TC inferior to FTC in Dutch cohort but interchangeable in other studies. (November-December HIV Treatment Bulletin)
- Equivalent efficacy with lower dose darunavir. (November-December HIV 2014, Treatment Bulletin)
- Lower dose efavirenz effective in two studies. (November-December HIV 2014, Treatment Bulletin)
- Sovaldi-Based Hep C Regimens Work Well in the Real World. (November 2014, Hepmag)
- Lower CNS Side Effects, Similar Efficacy for Doravirine Vs. Sustiva. (November 2014, Poz)
- Doravirine works as well as efavirenz with fewer CNS side-effects. (November 2014, AIDSmap)
- Once-daily dolutegravir superior to darunavir/ritonavir in 96-week follow-up. (November 2014, AIDSmap)
- Protease inhibitor monotherapy: darunavir/ritonavir less effective than three-drug therapy. (November 2014, AIDSmap)
- Do emtricitabine and lamivudine have similar virological efficacy when used in first-line HIV therapy? (November 2014, AIDSmap)
- Epivir and Tenofovir Appear Safe to Use During Breast-Feeding. (October 2014, Poz)
- Significantly Less BMD Loss With HIV Therapy That Doesn’t Contain Tenofovir/Emtricitabine. (October 2014, TheBodyPro)
- Complera Non-Inferior to Atripla and Better Tolerated, Study Finds. (October 2014, TheBodyPro)
- NNRTIs and protease inhibitors both good for first ART, channelling affects choices. (October 2014, AIDSmap)
- Factors Associated With 10 Years of Continuous Viral Load Suppression on HIV Treatment. (October 2014, TheBodyPro)
- HIV Attachment Inhibitor BMS-663068 Compares Well to Boosted Atazanavir at 24 Weeks. (October 2014, TheBodyPro)
- Sustiva (Efavirenz)-Free First-Line HIV Regimens Work Well. (October 2014, Poz)
- New FDA HIV Drug Approvals Unlikely to Have Much Impact, Unless… (September 2014, Journal Watch)
- HIV Combo Pill Less Toxic Thanks to New Form of Tenofovir. (September 2014, Poz)
- Atripla Is More Than the Sum of Its Three Parts. (September 2014, Poz)
- Longer time to virological failure and less drug resistance seen in people taking Atripla than in people taking separate drugs. (September 2014, AIDSmap)
- 3TC or FTC monotherapy suboptimal as a bridging strategy for adolescents. (August 2014, HIV i-Base)
- Tivicay Suppresses HIV Well, Even With Nuke Resistance. (August 2014, Poz)
- Selzentry (Maraviroc) Fails to Best Truvada as First-Line Therapy. (July 2014, Poz)
- Maraviroc fails to match tenofovir/emtricitabine for first-line HIV treatment. (July 2014, AIDSmap)
- Once-Daily Maraviroc Inferior to TDF/FTC in First-Line Regimens With Darunavir. (July 2014, NATAP)
- Maraviroc (MVC) Once Daily With Darunavir/Ritonavir(DRV/r) Compared to Tenofovir/Emtricitabine (TDF/FTC) With DRV/r: 48-Week Results From MODERN (Study A4001095) (July 2014, NATAP)
- Virologic Failure Predictors in SECOND-LINE Trial of Raltegravir vs NRTIs. (July 2014, NATAP)
- New Kidney Risk Score System May Guide HIV Med Choices. (April 2014, Poz)
- Isentress + Prezista Is Safe, Effective as First-Line HIV Therapy. (March 2014, Poz)
- 3 Regimens Hold HIV in Check Without Efavirenz. (March 2014, MedPage Today)
- Novel two-drug maintenance combination works at least as well as triple therapy: stage set for long-lasting injectable formulation. (March 2014, AIDSmap)
- Raltegravir has the edge over two protease inhibitors in three-drug comparison study. (March 2014, AIDSmap)
- Efavirenz Tops Lopinavir in Pregnancy. (March 2014, MedPage Today)
- In Battle of First-Line HIV Drugs, Raltegravir Beats Two Protease Inhibitors. (March 2014, TheBodyPro)
- Raltegravir plus boosted darunavir shown to be safe and effective for first-line ART. (March 2014, AIDSmap)
- Raltegravir Combo Gives New Anti-HIV Alternative. (March 2014, MedPage Today)
- Efficacy and Tolerability of Atazanavir, Raltegravir, or Darunavir With FTC/TDF: ACTG A5257. (March 2014, NATAP)
- FDA OKs Switching From Stable HIV Regimen to Complera. (December 2013, Poz)
- For women, HIV treatment based on atazanavir/ritonavir involves twice the risk of failure compared to efavirenz-containing therapy. (December 2013, AIDSmap)
- Systematic review and meta-analysis shows equivalence of 3TC and FTC. (November 2013, AIDSmap)
- SINGLE Study Underscores Waning of the Efavirenz Era – But Probably Just in the USA. (November 2013, Journal Watch)
- Dolutegravir matches or surpasses other regimens for first-line HIV treatment. (October 2013, AIDSmap)
- Dual-Drug Therapy of Lopinavir/Ritonavir and Lamivudine Non-Inferior to Triple-Drug Therapy. (October 2013, TheBodyPro)
- Kaletra and Epivir Dual Therapy Works as Well as Triple Combo. (October 2013, Poz)
- Racial Differences Seen in Comparison of First-Line Fixed-Dose Combinations. (October 2013, TheBodyPro)
- Cenicriviroc Shows Good Virologic Success, Tolerability Compared to Efavirenz. (October 2013, TheBodyPro)
- Eviplera works well regardless of viral load or CD4 count, may improve lipid levels. (October 2013, AIDSmap)
- Stribild is effective and well tolerated in older people with HIV. (October 2013, AIDSmap)
- Single-tablet regimen improves antiretroviral adherence and reduces hospitalisation. (September 2013, AIDSmap)
- Switching from Atripla to Eviplera reduces central nervous system side-effects. (September 2013, AIDSmap)
- New Tenofovir Has Lower Dose, Is Kinder to Kidneys and Bones. (September 2013, Poz)
- New tenofovir formulation works equally well with less effect on kidneys and bones. (September 2013, AIDSmap)
- Raltegravir is a good choice for people with HIV undergoing cancer chemotherapy. (September 2013, AIDSmap)
- Quad Pill Measures Up to Two Other HIV Drug Regimens. (July 2013, Poz)
- Making It Official: HIV Meds Have Improved Vastly. (July 2013, Poz)
- Battle of the Integrase Inhibitors: Dolutegravir Bests Isentress. (July 2013, Poz)
- Lower-dose lopinavir/ritonavir reduces side-effects, maintains viral control in Thai children. (July 2013, AIDSmap)
- Studies look at bone changes during second-line therapy, fractures, and HIV- and HCV-related bone loss. (July 2013, AIDSmap)
- First-line antiretroviral therapy has improved over time, meta-analysis shows. (July 2013, AIDSmap)
- Dolutegravir superior to raltegravir for treatment-experienced people with HIV. (July 2013, AIDSmap)
- Reduced efavirenz dose suppresses HIV as well as standard dose. (July 2013, AIDSmap)